Search

Your search keyword '"Wang, Xuya"' showing total 29 results
Start Over Author "Wang, Xuya" Search Limiters Full Text
29 results on '"Wang, Xuya"'

4. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial

Author

MS Medische Oncologie, Cancer, Oaknin, Ana, Moore, Kathleen, Meyer, Tim, López-Picazo González, José, Devriese, Lot A, Amin, Asim, Lao, Christopher D, Boni, Valentina, Sharfman, William H, Park, Jong Chul, Tahara, Makoto, Topalian, Suzanne L, Magallanes, Manuel, Molina Alavez, Alejandro, Khan, Tariq Aziz, Copigneaux, Catherine, Lee, Michelle, Garnett-Benson, Charlie, Wang, Xuya, Naumann, R Wendel, MS Medische Oncologie, Cancer, Oaknin, Ana, Moore, Kathleen, Meyer, Tim, López-Picazo González, José, Devriese, Lot A, Amin, Asim, Lao, Christopher D, Boni, Valentina, Sharfman, William H, Park, Jong Chul, Tahara, Makoto, Topalian, Suzanne L, Magallanes, Manuel, Molina Alavez, Alejandro, Khan, Tariq Aziz, Copigneaux, Catherine, Lee, Michelle, Garnett-Benson, Charlie, Wang, Xuya, and Naumann, R Wendel

Published
2024

7. An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer

Author

Ruggles, Kelly V., Tang, Zuojian, Wang, Xuya, Grover, Himanshu, Askenazi, Manor, Teubl, Jennifer, Cao, Song, McLellan, Michael D., Clauser, Karl R., Tabb, David L., Mertins, Philipp, Slebos, Robbert, Erdmann-Gilmore, Petra, Li, Shunqiang, Gunawardena, Harsha P., Xie, Ling, Liu, Tao, Zhou, Jian-Ying, Sun, Shisheng, Hoadley, Katherine A., Perou, Charles M., Chen, Xian, Davies, Sherri R., Maher, Christopher A., Kinsinger, Christopher R., Rodland, Karen D., Zhang, Hui, Zhang, Zhen, Ding, Li, Townsend, R. Reid, Rodriguez, Henry, Chan, Daniel, Smith, Richard D., Liebler, Daniel C., Carr, Steven A., Payne, Samuel, Ellis, Matthew J., and Fenyő, David

Published
2016
Full Text
View/download PDF

8. LINE-1 ORF2p expression is nearly imperceptible in human cancers

Author

Ardeljan, Daniel, Wang, Xuya, Oghbaie, Mehrnoosh, Taylor, Martin S., Husband, David, Deshpande, Vikram, Steranka, Jared P., Gorbounov, Mikhail, Yang, Wan Rou, Sie, Brandon, Larman, H. Benjamin, Jiang, Hua, Molloy, Kelly R., Altukhov, Ilya, Li, Zhi, McKerrow, Wilson, Fenyö, David, Burns, Kathleen H., and LaCava, John

Published
2019
Full Text
View/download PDF

10. China Artificial Intelligence Industry Insights

Author

Ebert, Christof and Wang, Xuya

Abstract

You may use Alipay, Baidu, or TikTok. But did you know that Chinese AI and IT increasingly influence everyday life? The rapid growth of tech business in China has contributed to the development of a dynamic and competitive landscape. This article provides insights.

Published
2024
Full Text
View/download PDF

12. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Author

Fizazi, Karim, primary, Retz, Margitta, additional, Petrylak, Daniel P, additional, Goh, Jeffrey C, additional, Perez-Gracia, Jose, additional, Lacombe, Louis, additional, Zschäbitz, Stefanie, additional, Burotto, Mauricio, additional, Mahammedi, Hakim, additional, Gravis, Gwenaelle, additional, Bastos, Diogo Assed, additional, McCune, Steven L, additional, Vázquez Limón, Juan Carlos, additional, Kwan, Edmond M, additional, Castellano, Daniel, additional, Fléchon, Aude, additional, Saad, Fred, additional, Grimm, Marc-Oliver, additional, Shaffer, David R, additional, Armstrong, Andrew J, additional, Bhagavatheeswaran, Prabhu, additional, Amin, Neha P, additional, Ünsal-Kaçmaz, Keziban, additional, Wang, Xuya, additional, Li, Jun, additional, Loehr, Andrea, additional, and Pachynski, Russell K, additional

Published
2022
Full Text
View/download PDF

13. Abstract CT023: Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses

Author

Lei, Ming, primary, Janjigian, Yelena Y., additional, Ajani, Jaffer A., additional, Moehler, Markus, additional, Wang, Xuya, additional, Shen, Lin, additional, Garrido, Marcelo, additional, Gallardo, Carlos, additional, Yamaguchi, Kensei, additional, Wyrwicz, Lucjan, additional, Skoczylas, Tomasz, additional, Bragagnoli, Arinilda, additional, Liu, Tianshu, additional, Tehfe, Mustapha, additional, Elimova, Elena, additional, Li, Mingshun, additional, Poulart, Valerie, additional, Wang, Yu, additional, Doshi, Parul, additional, and Shitara, Kohei, additional

Published
2022
Full Text
View/download PDF

14. A Novel Prognostic Signature Based on Glioma Essential Ferroptosis-Related Genes Predicts Clinical Outcomes and Indicates Treatment in Glioma

Author

Yun, Debo, primary, Wang, Xuya, additional, Wang, Wenbo, additional, Ren, Xiao, additional, Li, Jiabo, additional, Wang, Xisen, additional, Liang, Jianshen, additional, Liu, Jie, additional, Fan, Jikang, additional, Ren, Xiude, additional, Zhang, Hao, additional, Shang, Guanjie, additional, Sun, Jingzhang, additional, Chen, Lei, additional, Li, Tao, additional, Zhang, Chen, additional, Yu, Shengping, additional, and Yang, Xuejun, additional

Published
2022
Full Text
View/download PDF

15. Correction: Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Author

Huang, Kuan-lin, Li, Shunqiang, Mertins, Philipp, Cao, Song, Gunawardena, Harsha P., Ruggles, Kelly V., Mani, D. R., Clauser, Karl R., Tanioka, Maki, Usary, Jerry, Kavuri, Shyam M., Xie, Ling, Yoon, Christopher, Qiao, Jana W., Wrobel, John, Wyczalkowski, Matthew A., Erdmann-Gilmore, Petra, Snider, Jacqueline E., Hoog, Jeremy, Singh, Purba, Niu, Beifang, Guo, Zhanfang, Sun, Sam Qiancheng, Sanati, Souzan, Kawaler, Emily, Wang, Xuya, Scott, Adam, Ye, Kai, McLellan, Michael D., Wendl, Michael C., Malovannaya, Anna, Held, Jason M., Gillette, Michael A., Fenyö, David, Kinsinger, Christopher R., Mesri, Mehdi, Rodriguez, Henry, Davies, Sherri R., Perou, Charles M., Ma, Cynthia, Townsend, R. Reid, Chen, Xian, Carr, Steven A., Ellis, Matthew J., and Ding, Li

Published
2017
Full Text
View/download PDF

18. Comprehensive Scanning Mutagenesis of Human Retrotransposon LINE-1 Identifies Motifs Essential for Function

Author

Adney, Emily M., Ochmann, Matthias T., Sil, Srinjoy, Truong, David M., Mita, Paolo, Wang, Xuya, Kahler, David J., Fenyö, David, Holt, Liam J., and Boeke, Jef D.

Subjects
Models, Molecular, Transposable element, Retroelements, Mutant, Locus (genetics), Retrotransposon, Computational biology, Investigations, Biology, LINE-1, Open Reading Frames, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Cellular Genetics, Protein Domains, scanning mutagenesis, Genetics, Humans, Amino Acid Sequence, Nucleotide Motifs, Conserved Sequence, 030304 developmental biology, 0303 health sciences, Base Sequence, retrotransposon, RNA, L1, Reverse transcriptase, 3. Good health, Long Interspersed Nucleotide Elements, chemistry, Mutagenesis, Mutation, Human genome, Cell Nucleolus, 030217 neurology & neurosurgery, DNA, HeLa Cells
Abstract

Adney et al. describe the complete and comprehensive codon substitution mutagenesis of human retrotransposon LINE-1 using a synthetic DNA approach. This experiment is the first of its kind for any transposon..., Long Interspersed Nuclear Element-1 (LINE-1, L1) is the only autonomous active transposable element in the human genome. The L1-encoded proteins ORF1p and ORF2p enable the element to jump from one locus to another via a “copy-and-paste” mechanism. ORF1p is an RNA-binding protein, and ORF2p has endonuclease and reverse transcriptase activities. The huge number of truncated L1 remnants in the human genome suggests that the host has likely evolved mechanisms to prevent full L1 replication, and thereby decrease the proliferation of active elements and reduce the mutagenic potential of L1. In turn, L1 appears to have a minimized length to increase the probability of successful full-length replication. This streamlining would be expected to lead to high information density. Here, we describe the construction and initial characterization of a library of 538 consecutive trialanine substitutions that scan along ORF1p and ORF2p to identify functionally important regions. In accordance with the streamlining hypothesis, retrotransposition was overall very sensitive to mutations in ORF1p and ORF2p; only 16% of trialanine mutants retained near-wild-type (WT) activity. All ORF1p mutants formed near-WT levels of mRNA transcripts and 75% formed near-WT levels of protein. Two ORF1p mutants presented a unique nucleolar-relocalization phenotype. Regions of ORF2p that are sensitive to mutagenesis but lack phylogenetic conservation were also identified. We provide comprehensive information on the regions most critical to retrotransposition. This resource will guide future studies of intermolecular interactions that form with RNA, proteins, and target DNA throughout the L1 life cycle.

Published
2019
Full Text
View/download PDF

22. IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3/PD‐L1 pathway

Author

Yi, Li, primary, Guo, Gaochao, additional, Li, Jiabo, additional, Fan, Xiaoguang, additional, Li, Tao, additional, Tong, Luqing, additional, Liu, Peidong, additional, Wang, Xuya, additional, Yuan, Feng, additional, Yu, Shengping, additional, Huang, Qiang, additional, and Yang, Xuejun, additional

Published
2020
Full Text
View/download PDF

23. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma

Author

Tong, Luqing, primary, Li, Jiabo, additional, Li, Qiuying, additional, Wang, Xuya, additional, Medikonda, Ravi, additional, Zhao, Tianna, additional, Li, Tao, additional, Ma, Haiwen, additional, Yi, Li, additional, Liu, Peidong, additional, Xie, Yang, additional, Choi, John, additional, Yu, Shengping, additional, Lin, Yu, additional, Dong, Jun, additional, Huang, Qiang, additional, Jin, Xun, additional, Lim, Michael, additional, and Yang, Xuejun, additional

Published
2020
Full Text
View/download PDF

25. Breast tumors educate stromal tissue with individualized but coordinated proteomic signatures

Author

Wang, Xuya, Mooradian, Arshag D., Erdmann-Gilmore, Petra, Zhang, Qiang, Viner, Rosa, Davies, Sherri R., Huang, Kuan-lin, Bomgarden, Ryan, Van Tine, Brian A., Shao, Jieya, Ding, Li, Li, Shunqiang, Ellis, Matthew J., Rogers, John C., Townsend, R. Reid, Fenyö, David, and Held, Jason M.

Subjects
Male, Proteomics, Proteome, Breast Neoplasms, Xenograft Model Antitumor Assays, Article, Gene Expression Regulation, Neoplastic, Mice, Mice, Inbred NOD, Tumor Microenvironment, Animals, Humans, Female, Neoplasm Invasiveness, Neoplasm Metastasis, Stromal Cells
Abstract

Cancer forms specialized microenvironmental niches that promote local invasion and colonization. Engrafted patient-derived xenografts (PDXs) locally invade and colonize naïve stroma in mice while enabling unambiguous molecular discrimination of human proteins in the tumor from mouse proteins in the microenvironment. To characterize how patient breast tumors form a niche and educate naïve stroma, subcutaneous breast cancer PDXs were globally profiled by species-specific quantitative proteomics. Regulation of PDX stromal proteins by breast tumors was extensive, with 35% of the stromal proteome altered by tumors consistently across different animals and passages. Differentially regulated proteins in the stroma clustered into six signatures, which included both known and previously unappreciated contributors to tumor invasion and colonization. Stromal proteomes were coordinately regulated; however, the sets of proteins altered by each tumor were highly distinct. Integrated analysis of tumor and stromal proteins, a comparison made possible in these xenograft models, indicated that the known hallmarks of cancer contribute pleiotropically to establishing and maintaining the microenvironmental niche of the tumor. Education of the stroma by the tumor is therefore an intrinsic property of breast tumors that is highly individualized, yet proceeds by consistent, nonrandom, and defined tumor-promoting molecular alterations.

Published
2017

26. Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

Author

Mundt, Filip, primary, Rajput, Sandeep, additional, Li, Shunqiang, additional, Ruggles, Kelly V., additional, Mooradian, Arshag D., additional, Mertins, Philipp, additional, Gillette, Michael A., additional, Krug, Karsten, additional, Guo, Zhanfang, additional, Hoog, Jeremy, additional, Erdmann-Gilmore, Petra, additional, Primeau, Tina, additional, Huang, Shixia, additional, Edwards, Dean P., additional, Wang, Xiaowei, additional, Wang, Xuya, additional, Kawaler, Emily, additional, Mani, D.R., additional, Clauser, Karl R., additional, Gao, Feng, additional, Luo, Jingqin, additional, Davies, Sherri R., additional, Johnson, Gary L., additional, Huang, Kuan-lin, additional, Yoon, Christopher J., additional, Ding, Li, additional, Fenyö, David, additional, Ellis, Matthew J., additional, Townsend, R. Reid, additional, Held, Jason M., additional, Carr, Steven A., additional, and Ma, Cynthia X., additional

Published
2018
Full Text
View/download PDF

27. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Author

Huang, Kuan-lin, primary, Li, Shunqiang, additional, Mertins, Philipp, additional, Cao, Song, additional, Gunawardena, Harsha P., additional, Ruggles, Kelly V., additional, Mani, D. R., additional, Clauser, Karl R., additional, Tanioka, Maki, additional, Usary, Jerry, additional, Kavuri, Shyam M., additional, Xie, Ling, additional, Yoon, Christopher, additional, Qiao, Jana W, additional, Wrobel, John, additional, Wyczalkowski, Matthew A., additional, Erdmann-Gilmore, Petra, additional, Snider, Jacqueline E., additional, Hoog, Jeremy, additional, Singh, Purba, additional, Niu, Beifang, additional, Guo, Zhanfang, additional, Sun, Sam Qiancheng, additional, Sanati, Souzan, additional, Kawaler, Emily, additional, Wang, Xuya, additional, Scott, Adam, additional, Ye, Kai, additional, McLellan, Michael D., additional, Wendl, Michael C., additional, Malovannaya, Anna, additional, Held, Jason M., additional, Gillette, Michael A., additional, Fenyö, David, additional, Kinsinger, Christopher R., additional, Mesri, Mehdi, additional, Rodriguez, Henry, additional, Davies, Sherri R., additional, Perou, Charles M., additional, Ma, Cynthia, additional, Reid Townsend, R., additional, Chen, Xian, additional, Carr, Steven A., additional, Ellis, Matthew J., additional, and Ding, Li, additional

Published
2017
Full Text
View/download PDF

28. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Author

Huang, Kuan-lin, Li, Shunqiang, Mertins, Philipp, Cao, Song, Gunawardena, Harsha P., Ruggles, Kelly V., Mani, D. R., Clauser, Karl R., Tanioka, Maki, Usary, Jerry, Kavuri, Shyam M., Xie, Ling, Yoon, Christopher, Qiao, Jana W, Wrobel, John, Wyczalkowski, Matthew A., Erdmann-Gilmore, Petra, Snider, Jacqueline E., Hoog, Jeremy, Singh, Purba, Niu, Beifung, Guo, Zhanfang, Sun, Sam Qiancheng, Sanati, Souzan, Kawaler, Emily, Wang, Xuya, Scott, Adam, Ye, Kai, McLellan, Michael D., Wendl, Michael C., Malovannaya, Anna, Held, Jason M., Gillette, Michael A., Fenyö, David, Kinsinger, Christopher R., Mesri, Mehdi, Rodriguez, Henry, Davies, Sherri R., Perou, Charles M., Ma, Cynthia, Reid Townsend, R., Chen, Xian, Carr, Steven A., Ellis, Matthew J., and Ding, Li

Abstract

Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer proteomes. Here, we employed quantitative proteomics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows positive correlation between expression measurements from transcriptomic and proteomic analyses; further, gene expression-based intrinsic subtypes are largely re-capitulated using non-stromal protein markers. Proteogenomic analysis also validates a number of predicted genomic targets in multiple receptor tyrosine kinases. However, several protein/phosphoprotein events such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1 phosphosites are not readily explainable by genomic analysis, suggesting that druggable translational and/or post-translational regulatory events may be uniquely diagnosed by MS. Drug treatment experiments targeting HER2 and components of the PI3K pathway supported proteogenomic response predictions in seven xenograft models. Our study demonstrates that MS-based proteomics can identify therapeutic targets and highlights the potential of PDX drug response evaluation to annotate MS-based pathway activities.

Published
2017
Full Text
View/download PDF

29. A First Step towards a Clinical Decision Support System for Post-traumatic Stress Disorders.

Author

Ma S, Galatzer-Levy IR, Wang X, Fenyö D, and Shalev AY

Subjects
Algorithms, Decision Support Techniques, Feasibility Studies, Female, Humans, Male, Risk Factors, Decision Support Systems, Clinical, Stress Disorders, Post-Traumatic, Support Vector Machine
Abstract

PTSD is distressful and debilitating, following a non-remitting course in about 10% to 20% of trauma survivors. Numerous risk indicators of PTSD have been identified, but individual level prediction remains elusive. As an effort to bridge the gap between scientific discovery and practical application, we designed and implemented a clinical decision support pipeline to provide clinically relevant recommendation for trauma survivors. To meet the specific challenge of early prediction, this work uses data obtained within ten days of a traumatic event. The pipeline creates personalized predictive model for each individual, and computes quality metrics for each predictive model. Clinical recommendations are made based on both the prediction of the model and its quality, thus avoiding making potentially detrimental recommendations based on insufficient information or suboptimal model. The current pipeline outperforms the acute stress disorder, a commonly used clinical risk factor for PTSD development, both in terms of sensitivity and specificity.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results